Smith & Nephew plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on June 6, 2025, serves as a notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. The filing is made in accordance with the UK Market Abuse Regulation. The reporting period covers transactions executed on June 4, 2025.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
- Instrument: Smith & Nephew plc SPON ADR (American Depositary Shares)
- ISIN: US83175M2052
- Transaction Price: $29.3442 per share
- Exchange: New York Stock Exchange
Material Changes and Transaction Details
The filing discloses purchases made by five executives through the Company's Employee Stock Purchase Plan and Dividend Re-Investment Plan following the 2024 final dividend payment on May 28, 2025. These are not open market trades but plan-driven acquisitions.
| Executive Name | Title | Volume (Shares) |
|---|---|---|
| Craig Gaffin | President, Global Orthopaedics | 33.73275 |
| Mizanu Kebede | Chief Quality & Regulatory Affairs Officer | 19.37144 |
| Deepak Nath | Chief Executive Officer | 35.79737 |
| Paul Connolly | President, Global Operations | 35.64110 |
| Scott Schaffner | President, Sports Medicine | 46.62612 |
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of unusual items. It is a regulatory compliance document regarding insider trading disclosures.
Key Facts for Investor Verification
- Verify that the share purchases were executed strictly through the Employee Stock Purchase Plan and Dividend Re-Investment Plan as stated.
- Confirm the total volume of shares purchased by the CEO and other PDMRs against the company's total outstanding share count to assess significance.
- Note that the transaction price of $29.3442 reflects the price on June 4, 2025, and should be compared to the current market price for valuation context.
- Ensure no other undisclosed transactions by these individuals occurred outside of the plan during this period.